Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) Director Leonard Sank acquired 4,497 shares of the business’s stock in a transaction dated Thursday, July 18th. The stock was purchased at an average cost of $3.86 per share, with a total value of $17,358.42. Following the transaction, the director now owns 315,482 shares of the company’s stock, valued at $1,217,760.52. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.
Leonard Sank also recently made the following trade(s):
- On Tuesday, July 16th, Leonard Sank acquired 20,000 shares of Oramed Pharmaceuticals stock. The stock was purchased at an average cost of $3.47 per share, with a total value of $69,400.00.
- On Thursday, July 11th, Leonard Sank acquired 1,320 shares of Oramed Pharmaceuticals stock. The stock was purchased at an average cost of $3.22 per share, with a total value of $4,250.40.
NASDAQ:ORMP opened at $3.87 on Friday. The firm has a 50 day moving average price of $3.42. The firm has a market capitalization of $68.83 million, a price-to-earnings ratio of -4.50 and a beta of 1.37. Oramed Pharmaceuticals, Inc. has a 1-year low of $2.78 and a 1-year high of $5.89.
Separately, HC Wainwright reissued a “buy” rating on shares of Oramed Pharmaceuticals in a research report on Wednesday, June 19th.
An institutional investor recently raised its position in Oramed Pharmaceuticals stock. BlackRock Inc. increased its position in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) by 137.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,343 shares of the biotechnology company’s stock after buying an additional 40,114 shares during the period. BlackRock Inc. owned about 0.40% of Oramed Pharmaceuticals worth $208,000 as of its most recent SEC filing. Institutional investors and hedge funds own 6.18% of the company’s stock.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.
Featured Story: Return on Equity (ROE)
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.